Bristol Myers Squibb posts solid quarter with $13B revenue

• Bristol Myers Squibb reported second-quarter 2026 revenues of $13 billion, reflecting a 6% year-over-year increase.
• The company recorded a GAAP earnings per share of $1.62 and a non-GAAP earnings per share of $2.04.
• The pharmaceutical developer stated that strong growth portfolio revenues prompted management to raise its full-year financial guidance.

Bristol Myers Squibb (NYSE:BMY) reported second-quarter 2026 revenues of $13.0 billion, representing a 6% increase from the prior year.

This top-line performance was supported by a 15% increase in the growth portfolio, which generated $7.6 billion.

The pharmaceutical manufacturer recorded a GAAP earnings per share of $1.62 alongside a non-GAAP earnings per share of $2.04.

Excluding foreign exchange impacts, overall corporate revenues increased by 5% and the growth portfolio expanded by 14%.

Following the announcement, Bristol Myers Squibb's share price was down at $63.36.

Management stated that the company expects full-year 2026 revenues to range between $49 billion and $50 billion.

The business also raised its non-GAAP earnings guidance, stating it expects between $6.75 and $7 per share for the year.